On June 10, Potiga (ezogabine) tablets were approved by FDA for use as an add-on medication to treat seizures associated with epilepsy in adults. Potiga is approved for the cure of partial seizures.
Seizures represent a sudden violent uncontrollable shaking of the body parts in epilepsy i.e. a disease in which the activity of nerve cells in the brain is increased. Partial seizures affect a localized or limited area of the brain and have the ability of spreading to other parts of the brain.
Mechanism of action of ezogabine (Potiga):
It is a first neuronal potassium channel opener. It reduces excitability through the stabilization of neuronal potassium channels in an “open” position. Although the mechanism of action of this drug is still to be firmly established.
Side effects of ezogabine:
It may cause fatigue, vertigo i.e. spinning sensation, confusion, dizziness, problems with co-ordination and double vision. Memory impairment and lack of strength can also be occurred.
Urinary retention is also a unique side effect. Certain neuro-psychiatric symptoms may also develop such as hallucinations and confusion but these symptoms are resolved within seven days after stopping the medication.
Potiga was developed by Valeant Pharmaceuticals North America of Durham, N.C., and will be distributed by GlaxoSmithKline of Research Triangle Park, N.C.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm258834.htm accessed June 14, 2011.